We are advising Natus Medical on the transaction

Davis Polk is advising Natus Medical Incorporated on its approximately $1.2 billion acquisition by ArchiMed Group. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions, including approval by Natus shareholders and receipt of regulatory approvals.

Natus delivers innovative and trusted solutions to screen, diagnose and treat disorders affecting the brain, neural pathways and eight sensory nervous systems to advance the standard of care and improve patient outcomes and quality of life. With offices in the United States and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries.

The Davis Polk corporate team includes partners Paul S. Scrivano and Evan Rosen and associates Christine Choi and Rong (Fiona) Huang. Partner Jennifer S. Conway and counsel Kevin A. Brown are providing executive compensation advice. Partner David R. Bauer is providing intellectual property advice. Partner Corey M. Goodman is providing tax advice. Partner Hilary Dengel is providing finance advice. Partner Howard Shelanski is providing antitrust and competition advice. Members of the Davis Polk team are based in the Northern California, New York and Washington DC offices.